Femble, a femtech startup based in Austria, has secured €350,000 in angel funding and announced a strategic pivot from its original menstrual cycle app to a platform that helps doctors become trusted health influencers for their patients. Founded in November 2020, Femble initially developed a B2C app for menstrual health issues, building a community of over 40,000 women and dozens of doctors.…
BillionToOne has announced that its UNITY Non-Invasive Prenatal Test (NIPT) for fetal antigens is being adopted by Maternal-Fetal Medicine (MFM) doctors in maternity health deserts, providing an alternative to weekly Doppler ultrasounds for high-risk pregnancies. The UNITY Fetal Antigen NIPT screens patients who are alloimmunized to certain antigens for hemolytic disease of the fetus and newborn (HDFN), a blood disorder where a…
Bioceptive and Trimedic have announced a letter of intent to establish a joint venture aimed at bringing the FDA-approved Cervical Suction Retractor (CSR) to market in Canada and the United States. The device offers an alternative to the traditional tenaculum used in gynecological procedures, including IUD insertion. The CSR uses gentle suction instead of the pinching mechanism of the tenaculum, which can…
Ovesse, a vaginal oestrogen cream, has become the first of its kind available over-the-counter in the UK offering new possibilities for millions of postmenopausal women suffering from vaginal atrophy, a condition affecting approximately 50% of women after menopause. Ovesse is a prescription-strength vaginal cream containing estriol, a naturally occurring oestrogen hormone. It’s designed to treat vaginal atrophy by replacing the oestrogen no…
Evernow has announced a partnership with Clearblue to provide users of the Clearblue Menopause Stage Indicator access to specialized menopause healthcare. The collaboration aims to reach up to 35 million women in menopause transition, offering them a path from at-home testing to professional care. Users of Clearblue’s Menopause Stage Indicator, launched in August 2023, will be eligible for a one-month free care…
Bayer has announced that elinzanetant met all primary and secondary endpoints in its Phase III OASIS 4 study for treating moderate to severe vasomotor symptoms (hot flashes) caused by breast cancer treatments. The trial focused on women with or at high risk of developing hormone receptor-positive breast cancer who experience hot flashes due to adjuvant endocrine therapy. The study demonstrated statistically significant…
Hippocratic AI has launched its Healthcare AI Agent App Store, a platform enabling clinicians to create AI solutions for patient care across multiple specialties. The platform’s founding clinicians have already developed over 300 AI agents covering more than 25 medical specialties. The founding contributors include specialists across various healthcare fields. Among them, Dr. Vanessa Dorismond focuses on cervical cancer check-ins, Kristina Dulaney…
Eli Health has unveiled the Hormometer, a saliva-based hormone analysis device that transforms smartphones into portable hormone analyzers, at CES 2025 this week. The device also won Best of Innovation in the CES Innovation Awards 2025 program for Digital Health. “At Eli Health, we are creating unprecedented access to hormone health insights, providing individuals with the tools they need to better understand…
